ReviewFrontiers in pharmacology2019
Comprehensive Evaluation of Organotypic and Microphysiological Liver Models for Prediction of Drug-Induced Liver Injury.
Review in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Assessing drug-induced liver injury liabilities in human and animal hepatocytes under static and perfused spheroid culture conditions.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis.Frontiers in bioengineering and biotechnology · 2026Article
- In vitro liver models for toxicological research.Drug metabolism and pharmacokinetics · 2025Review
- Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases.Biomolecules · 2025Review
- HIVIL: A humanNAM journal · 2025Article
- Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening.Biomolecules · 2024Review
- Hepatic spheroid-on-a-chip: Fabrication and characterization of a spheroid-basedBiomicrofluidics · 2024Article
- Compound Absorption in Polymer Devices Impairs the Translatability of Preclinical Safety Assessments.Advanced healthcare materials · 2024Article
- Cryopreservation of assay-ready hepatocyte monolayers by chemically-induced ice nucleation: preservation of hepatic function and hepatotoxicity screening capabilities.Biomaterials science · 2023Article
- Review
- Liver three-dimensional cellular models for high-throughput chemical testing.Cell reports methods · 2023Review
- Recent advances in liver-on-chips: Design, fabrication, and applications.Smart medicine · 2023Review
- Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology.Communications medicine · 2022Article
- Liver-on-a-chip: Considerations, advances, and beyond.Biomicrofluidics · 2022Review
- Introducing CELLBLOKSIn vitro models · 2022Article
- Three-Dimensional Organoids as a Model to Study Nonalcoholic Fatty Liver Disease.Seminars in liver disease · 2022Review
- Using liver models generated from human-induced pluripotent stem cells (iPSCs) for evaluating chemical-induced modifications and disease across liver developmental stages.Toxicology in vitro : an international journal published in association with BIBRA · 2022Review
- Pre-clinical 2D and 3D toxicity response to a panel of nanomaterials; comparative assessment of NBM-induced liver toxicity.Drug delivery and translational research · 2022Article
- Obesity III: Obesogen assays: Limitations, strengths, and new directions.Biochemical pharmacology · 2022Review
- Combination of Vitamin C and Curcumin Safeguards Against Methotrexate-Induced Acute Liver Injury in Mice by Synergistic Antioxidant Effects.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced liver injury (DILI) is a major concern for the pharmaceutical industry and constitutes one of the most important reasons for the termination of promising drug development projects. Reliable prediction of DILI liability in preclinical stages is difficult, as current experimental model systems do not accurately reflect the molecular phenotype and functionality of the human liver. As a result, multiple drugs that passed preclinical safety evaluations failed due to liver toxicity in clinical trials or postmarketing stages in recent years. To improve the selection of molecules that are taken forward into the clinics, the development of more predictive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.